Associated Papers
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.
Maloberti T et al.
Diagnostics (basel, Switzerland), 2024
Landscape of Genetic Mutations in Appendiceal Cancers.
Constantin M et al.
Cancers, 2023
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions.
Zaremba A et al.
Cancers, 2022
Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
Affolter KE et al.
Neoplasia (new York, N.y.), 2021
Role of miR-214 in regulation of β-catenin and the malignant phenotype of melanoma.
Prabhakar K et al.
Molecular Carcinogenesis, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
Newell F et al.
Nature Communications, 2019
Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience.
Bandoh N et al.
Oncology Letters, 2018
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
Abida W et al.
Jco Precision Oncology, 2017
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).
Sun QY et al.
Leukemia, 2017
Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases.
Malapelle U et al.
Journal of Clinical Pathology, 2016
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.
Rennert H et al.
Npj Genomic Medicine, 2016
RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM et al.
Endocrine-related Cancer, 2015
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R et al.
Thyroid : Official Journal of the American Thyroid Association, 2013
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD et al.
Neoplasia (new York, N.y.), 2010
Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma.
Kulda V et al.
Cancer Genomics & Proteomics, 0